An initial jump has been followed by a deeper drop in the share value of US biotech Aimmune Therapeutics (Nasdaq: AIMT) after the presentation of some pivotal trial results.
News reports on Tuesday initially claimed that Aimmune might have finally cracked the long quest to find a treatment for patients with a peanut allergy after the company announced that the 554-patient Phase III PALISADE trial had met its primary endpoint.
More than two thirds of patients aged from four to 17 years tolerated at least a 600mg dose of peanut protein in the exit food challenge after being treated with Aimmune’s AR101 for a year, compared to 4% of those on placebo. Half of AR101 patients tolerated a 1000mg dose, compared to 2.4% of the placebo arm.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze